Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Study Summary

Previous related pageVitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full StudyNext related pageVitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study
Study at a glance

How was vitamin D studied in bone health and fracture prevention?

This page compares mouse experiments on bone and mineral regulation with a large human trial of vitamin D3 and fractures. The experiments examined how minerals enter bone and how bone cells respond to vitamin D. These processes matter, but changes in them do not automatically prove that supplements prevent broken bones.

What happened to bone health when vitamin D signals changed in mice?

Mice with reduced responses to vitamin D in the intestine absorbed less calcium. Their blood calcium stayed similar to that in control mice while their bones deteriorated. Other experiments linked vitamin D signals in particular bone cells to mineral loss under toxic exposure to calcitriol, the active vitamin D hormone. Changes in cartilage and phosphate-regulating signals also affected developing bone. Some differences disappeared as the mice matured, and dietary changes did not correct every problem.

Did vitamin D supplements reduce fractures in the VITAL trial?

The VITAL analysis included 25,871 adults who were not selected because they had vitamin D deficiency or osteoporosis, a condition that weakens bones. Vitamin D3 at 2,000 international units (IU) daily did not clearly reduce fractures compared with placebo over a median follow-up of 5.3 years. A first fracture occurred in 769 of 12,927 people receiving vitamin D and 782 of 12,944 receiving placebo. Hip-fracture results also showed no clear benefit.

Do these findings apply to people with severe vitamin D deficiency?

Very few measured VITAL participants had severely low vitamin D. The result therefore does not show that treating severe deficiency or osteomalacia, a bone-softening condition, is ineffective. The mouse experiments used genetic changes or toxic active-hormone exposure, which differ from ordinary vitamin D3 supplementation. Together, these studies show neither a universal bone benefit nor universal bone harm. Blood-test changes and bone-cell signals must be distinguished from whether people actually broke bones.

Read the full article below ↓

Vitamin D-related signalling affects mineral supply and bone-cell behaviour in experimental models, but those mechanisms do not automatically establish fracture prevention with supplements. The selected studies distinguish mineralisation, remodelling and clinical fractures, preserving the different exposures and populations involved. For the detailed analysis, see Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study.

Intestinal absorption and local signalling both mattered

Lieben’s intestinal-VDR knockout mice maintained serum calcium through compensatory hormonal changes while skeletal mineralisation and cortical integrity deteriorated. Both mineral release and reduced incorporation into bone contributed. A mineral-rich rescue diet altered the phenotype, supporting the importance of supply.

A mature osteoblast/osteocyte VDR-deletion model was largely normal at baseline but protected against high-calcitriol mineralisation impairment. These findings concern particular tissues and conditions, not a universal beneficial or harmful effect of vitamin D in bone. They connect Vitamin D and Calcium with Vitamin D and Calcium Physiology while showing that serum calcium is not a direct measure of skeletal stores.

Cell-lineage experiments separated signalling from resorption

Mori used a toxic active-calcitriol regimen in mice: 5 micrograms/kg daily for four days. Anti-RANKL treatment blocked osteoclast and CTX responses, but only partly prevented calcium and FGF23 effects. Osteoblast-lineage VDR deletion protected against key proresorptive responses.

This supports a specific mechanism linking osteoblast-lineage signalling with osteoclast output. It does not establish harm from ordinary oral vitamin D3. Small groups, high-dose toxicity and the use of earlier evidence in the final schematic limit broader conclusions.

Masuyama’s juvenile cartilage-VDR model altered osteoclast recruitment and osteoblast-associated FGF23, with several skeletal differences normalising by eight weeks. The responsible cartilage-derived factor remained unknown. Developmental recruitment is not interchangeable with adult remodelling or human fracture risk.

Phosphate regulation was essential to the experimental system

Shimada’s global Fgf23 deletion produced high phosphate and calcitriol, abnormal mineralised bone, increased osteoid and early mortality. Partial dietary rescue did not correct everything. Vitamin D and Phosphate Regulation provides the wider relationship, but the model does not prove that calcitriol alone caused every abnormality.

The distinction between active hormone and its precursor, explained in Vitamin D Activation, is essential throughout these experiments. Genetic deletion and toxic calcitriol exposure are not equivalent to nutritional supplementation.

VITAL did not show a fracture reduction in its population

LeBoff’s VITAL analysis included 25,871 adults not selected for deficiency or osteoporosis, comparing 2,000 IU vitamin D3 daily with placebo over a median 5.3 years. First total fractures occurred in 769/12,927 versus 782/12,944 participants: hazard ratio 0.98, 95% confidence interval 0.89 to 1.08, p=.70. Nonvertebral and hip-fracture comparisons were also null.

Mean baseline vitamin D was 30.7 ng/mL, and only 2.4% of measured participants were below 12 ng/mL. Outside supplements were permitted within specified limits. The result does not establish ineffectiveness of treating severe deficiency or osteomalacia.

PTH decreased in a measured subset without an established overall fracture benefit. This is a biochemical response, not proof of fracture mediation. The main text and tables were examined; unavailable graphics and supplements were not used for subgroup claims.

Conclusion

The experimental studies explain specific skeletal mechanisms, while VITAL answers a bounded clinical supplementation question. Neither universal bone benefit nor universal bone harm follows from combining them. Interventions, cell targets, mineral conditions and measured outcomes must remain separate.

Primary source and publication details

LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.

Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.

Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.

Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.

Related reading

Original sources

Source

Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults

Published in The New England journal of medicine (2022).

Publication details

LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. The New England journal of medicine. 2022;387(4):299-309. DOI 10.1056/nejmoa2202106. PMID 35939577.

Read more →
Source

Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization

Published in The Journal of clinical investigation (2012).

Publication details

Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. The Journal of clinical investigation. 2012;122(5):1803-1815. DOI 10.1172/jci45890. PMID 22523068.

Read more →
Source

Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts

Published in The Journal of clinical investigation (2006).

Publication details

Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. The Journal of clinical investigation. 2006;116(12):3150-3159. DOI 10.1172/jci29463. PMID 17099775.

Read more →
Source

The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo

Using osteoblast-lineage-specific VDR conditional knockout (Ob-VDR-cKO) mice, we examined whether proresorptive activity induced by the high-dose 1α,25(OH)2D3 was also mediated by VDR in osteoblast-lineage cells.

Publication details

Mori T, Horibe K, Koide M, Uehara S, Yamamoto Y, Kato S, Yasuda H, Takahashi N, Udagawa N, Nakamichi Y. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo. Endocrinology. 2020;161(11):bqaa178. DOI 10.1210/endocr/bqaa178. PMID 32987399.

Read more →
Source

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

Published in The Journal of clinical investigation (2004).

Publication details

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-568. DOI 10.1172/jci19081. PMID 14966565.

Read more →